| Literature DB >> 27797934 |
Sheraz R Markar1, Hugh Mackenzie1, Melody Ni1, Jeremy R Huddy1, Alan Askari2, Omar Faiz1,2, S Michael Griffin3, Laurence Lovat4, George B Hanna1.
Abstract
OBJECTIVE: Endoscopic mucosal resection (EMR) is established for the management of benign and early malignant upper GI disease. The aim of this observational study was to establish the effect of endoscopist procedural volume on mortality.Entities:
Keywords: GASTRIC CANCER; OESOPHAGEAL CANCER; THERAPEUTIC ENDOSCOPY
Mesh:
Year: 2016 PMID: 27797934 PMCID: PMC5754854 DOI: 10.1136/gutjnl-2015-311237
Source DB: PubMed Journal: Gut ISSN: 0017-5749 Impact factor: 23.059
Preoperative demographics for patients undergoing endoscopic mucosal resection
| Preoperative demographic | Non-cancer patients (%) | Patients with oesophagogastric cancer (%) |
|---|---|---|
| Age ≥70 years | 4669 (46.8) | 694 (64.4) |
| Male ratio | 5109 (51.2) | 709 (65.8) |
| Congestive cardiac failure | 93 (0.9) | 13 (1.2) |
| Ischaemic heart disease | 389 (3.9) | 69 (6.4) |
| Liver disease | 74 (0.7) | 5 (0.5) |
| Peripheral vascular disease | 40 (0.4) | 12 (1.1) |
| Pulmonary disease | 542 (5.4) | 94 (8.7) |
| Renal disease | 118 (1.2) | 15 (1.4) |
| Charlson Comorbidity Index ≥3 | 424 (4.3) | 687 (63.7) |
Changes in clinical outcomes from EMR before and after change point in RA-CUSUM curve analysis for endoscopist proficiency gain (A) non-cancer patients and (B) patients with oesophagogastric cancer
| Outcome | Change point | Overall rate | Before change point | After change point | p Value |
|---|---|---|---|---|---|
| (A) Non-cancer patients | |||||
| Emergency intervention | No PGC | – | – | – | – |
| 30-day mortality | 2 cases | 1.0% (0.8% to 1.2%) | 1.8% (1.4% to 2.3%) | 0.5% (0.4% to 0.7%) | <0.001 |
| 90-day mortality | 2 cases | 2.2% (2.0% to 2.5%) | 3.6% (3.1% to 4.3%) | 1.3% (1.1% to 1.7%) | <0.001 |
| (B) Patients with oesophagogastric cancer | |||||
| Emergency intervention | 1 case | 0.6% (0.3% to 1.3%) | 1.5% (0.7% to 3.2%) | 0.1% (0.0% to 0.8%) | 0.009 |
| 30-day mortality | 4 cases | 3.1% (2.2% to 4.3%) | 4.5% (3.2% to 6.3%) | 0.3% (0.1% to 1.5%) | <0.001 |
| 90-day mortality | 2 cases | 6.8% (5.4% to 8.4%) | 10.8% (8.4% to 13.6%) | 2.6% (1.5% to 4.3%) | <0.001 |
| Re-intervention | 43 cases | 23.6% (21.1% to 26.2%) | 24.6% (22.0% to 27.3%) | 10.8% (5.4% to 19.4%) | 0.005 |
| Oesophagectomy/gastrectomy | 14.6% (12.9% to 16.8%) | 15.3% (13.2% to 17.6%) | 5.3% (2.1% to 12.8%) | 0.017 | |
| Repeat EMR | 9.0% (7.4% to 10.9%) | 9.3% (7.6% to 11.2%) | 5.3% (2.1% to 12.8%) | 0.238 | |
Emergency intervention was defined as an acute emergency operation or endoscopic stent insertion performed within 14 days of the primary EMR procedure.
Re-intervention was defined as repeat EMR, oesophagectomy or gastrectomy for the treatment of cancer at least 30 days following the initial EMR procedure.
EMR, endoscopic mucosal resection; PGC, proficiency gain curve; RA-CUSUM, risk-adjusted cumulative sum.
Changes in clinical outcomes from EMR before and after threshold in RA-CUSUM curve analysis for patients with cancer by (A) annual endoscopist volume and (B) annual hospital volume
| Variable | Volume threshold per year | Overall rate | Below | Above | p Value |
|---|---|---|---|---|---|
| Endoscopist annual volume | |||||
| Emergency intervention | 1 case | 0.6% (0.3% to 1.3%) | 1.8% (0.8% to 3.9%) | 0.1% (0.0% to 0.7%) | 0.002 |
| 30-day mortality | 2 cases | 3.1% (2.2% to 4.3%) | 6.1% (4.3% to 8.5%) | 0.4% (0.1% to 1.3%) | <0.001 |
| 90-day mortality | 2 cases | 6.8% (5.4% to 8.4%) | 12.0% (9.4% to 15.1%) | 2.1% (1.2% to 3.7%) | <0.001 |
| Re-intervention | 8 cases | 23.6% (21.1% to 26.8%) | 24.2% (21.1% to 27.3%) | 17.5% (13.5% to 22.2%) | 0.033 |
| Hospital annual volume | |||||
| Emergency intervention | 5 cases | 0.6% (0.3% to 1.3%) | 1.6% (0.7% to 3.6%) | 0.3% (0.1% to 1.0%) | 0.016 |
| 30-day mortality | 8 cases | 3.1% (2.2% to 4.3%) | 5.3% (3.6% to 7.7%) | 1.2% (0.6% to 2.4%) | <0.001 |
| 90-day mortality | 8 cases | 6.8% (5.4% to 8.4%) | 10.8% (8.3% to 13.8%) | 3.4% (2.2% to 5.2%) | <0.001 |
| Re-intervention | No curve | 23.6% (21.1% to 26.8%) | NA | NA | NA |
Emergency intervention was defined as an acute emergency operation or endoscopic stent insertion performed within 14 days of the primary EMR procedure.
Re-intervention was defined as repeat EMR, oesophagectomy or gastrectomy for the treatment of cancer at least 30 days following the initial EMR procedure.
EMR, endoscopic mucosal resection; RA-CUSUM, risk-adjusted cumulative sum.
Figure 1National risk-adjusted cumulative sum (RA-CUSUM) curves of non-cancer endoscopic mucosal resection (EMR) cases and of EMR for oesophagogastric cancer showing significant change points in clinical outcomes for EMR during endoscopist proficiency gain.
Figure 2Thirty-day mortality and 90-day mortality cumulative moving average (CMA) curves for low volume (LV) and high volume (HV) endoscopists, demonstrating similar clinical outcomes during the early component of learning endoscopic mucosal resection.
Hierarchical multivariate regression analysis for 30-day mortality following upper GI EMR
| Variable | Cancer cohort | Non-cancer cohort | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Age ≥70 years | 3.14 | 1.29 to 7.60 | 0.011 | 2.01 | 1.33 to 3.04 | 0.001 |
| Female gender | 1.08 | 0.55 to 2.10 | 0.821 | 0.54 | 0.36 to 0.82 | 0.003 |
| Charlson Comorbidity Index ≥3 | 2.22 | 1.06 to 4.69 | 0.036 | 5.18 | 3.13 to 8.59 | <0.001 |
| Endoscopist volume* | 0.34 | 0.17 to 0.68 | 0.002 | 0.55 | 0.32 to 0.96 | 0.034 |
| Hospital volume† | 0.69 | 0.34 to 1.37 | 0.283 | 0.74 | 0.45 to 1.21 | 0.230 |
| Cancer surgeon endoscopist | 0.72 | 0.27 to 1.88 | 0.502 | – | – | – |
*Endoscopist volume threshold of two cases per year used to dichotomise study cohort.
†Hospital volume of eight cases per year used to dichotomise study cohort.
EMR, endoscopic mucosal resection.